樂
樂觀
樂觀 · 25%MIST
$2.13
情境價格
$0.693
-0.072 (-10.36%)收盤時
Loading chart…
- 最高
- 0.785
- 開盤
- 0.761
- 成交量加權均價
- 0.72
- 成交量
- 1.19M
- 市值
- 68.71M
- 最低
- 0.675
- 成交金額
- 856.11K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -0.08
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
AI 分析 of Milestone Pharmaceuticals Inc (MIST)
買進Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
估值指標
Milestone Pharmaceuticals Inc（MIST）目前預期本益比為 0.00，5 年平均預期本益比為 -2.72。
Alphio AI 對 MIST 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
5.011-04NewsfilterMilestone Pharmaceuticals Grants 33,000 Stock Options to New Employee
9.009-27NASDAQ.COMMilestone Pharmaceuticals Initiates Phase 3 Trial for Etripamil
9.009-03NASDAQ.COMMilestone Pharmaceuticals Secures Approval for Etripamil in China
- 8.509-03Newsfilter
Everest Medicines to Lead Etripamil Commercialization in Greater China
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
MIST 常見問題 —— 由 Alphio AI 解答
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。